Otsuka Holdings Co., Ltd.
TSE-4578
Company Overview
Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.
Name
Otsuka Holdings Co., Ltd.
CEO
Mr. Tatsuo Higuchi
Website
www.otsuka.com
Sector
Pharmaceuticals
Year Founded
1921
Profile
Market Cap
¥4,344.69B
EV
¥4,151.7B
Shares Out
541.46M
Revenue
¥2,179.96B
Employees
34,388
Margins
Gross
70.66%
EBITDA
20.85%
Operating
16.22%
Pre-Tax
6.7%
Net
5.82%
FCF
—
Returns (5Yr Avg)
ROA
4.87%
ROTA
9.11%
ROE
6.8%
ROCE
8.56%
ROIC
7.15%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
¥8,450
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
¥485.89B
Net Debt
-¥237.93B
Debt/Equity
0.09
EBIT/Interest
40.21
Growth (CAGR)
Rev 3Yr
14.66%
Rev 5Yr
10.14%
Rev 10Yr
—
Dil EPS 3Yr
-6.03%
Dil EPS 5Yr
8.18%
Dil EPS 10Yr
—
Rev Fwd 2Yr
5.68%
EBITDA Fwd 2Yr
40.59%
EPS Fwd 2Yr
47.43%
EPS LT Growth Est
26.9%
Dividends
Yield
—
Payout
51.35%
DPS
¥120
DPS Growth 3Yr
6.27%
DPS Growth 5Yr
3.71%
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
5.89%